---
title: "Iguratimod - Rheumatoid Arthritis"
sidebar: mydoc_sidebar
permalink: db12233-mesh-d001172-1.html
toc: false 
---


Path ID: `DB12233_MESH_D001172_1`
{% include image.html url="images/db12233-mesh-d001172-1.png" file="db12233-mesh-d001172-1.png" alt="db12233-mesh-d001172-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| <a href="https://identifiers.org/MESH:C519076">MESH:C519076 </a> | iguratimod | Drug |
| <a href="https://identifiers.org/UniProt:P3535">UniProt:P3535 </a> | Prostaglandin G/H synthase 2 | Protein |
| <a href="https://identifiers.org/UniProt:O00463">UniProt:O00463 </a> | TNF receptor-associated factor 5 | Protein |
| <a href="https://identifiers.org/UniProt:Q14164">UniProt:Q14164 </a> | Inhibitor of nuclear factor kappa-B kinase subunit epsilon | Protein |
| <a href="https://identifiers.org/UniProt:O43734">UniProt:O43734 </a> | E3 ubiquitin ligase TRAF3IP2 | Protein |
| <a href="https://identifiers.org/UniProt:A6MUU8">UniProt:A6MUU8 </a> | Macrophage migration inhibitory factor | Protein |
| <a href="https://identifiers.org/reactome:R-HSA-448424">reactome:R-HSA-448424 </a> | Interleukin-17 signaling | Pathway |
| <a href="https://identifiers.org/reactome:R-HSA-5668541">reactome:R-HSA-5668541 </a> | TNFRSF mediated non-canonical NF-kB pathway | Pathway |
| <a href="https://identifiers.org/GO:0007253">GO:0007253 </a> | cytoplasmic sequestering of NF-kappaB | BiologicalProcess |
| <a href="https://identifiers.org/GO:0006954">GO:0006954 </a> | inflammatory response | BiologicalProcess |
| <a href="https://identifiers.org/MESH:D001172">MESH:D001172 </a> | Rheumatoid arthritis | Disease |
|------------|------|---------|

## Relationships


NOTE: predicates are annotated in <a href="https://github.com/biolink/biolink-model/releases/tag/v1.3.0">Biolink Model (v1.3.0)</a>

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Iguratimod | DECREASES ACTIVITY OF | Prostaglandin G/H Synthase 2 |
| Iguratimod | NEGATIVELY REGULATES | Macrophage Migration Inhibitory Factor |
| Macrophage Migration Inhibitory Factor | POSITIVELY REGULATES | Interleukin-17 Signaling |
| Iguratimod | NEGATIVELY REGULATES | Tnf Receptor-Associated Factor 5 |
| Tnf Receptor-Associated Factor 5 | POSITIVELY REGULATES | Interleukin-17 Signaling |
| Iguratimod | NEGATIVELY REGULATES | E3 Ubiquitin Ligase Traf3Ip2 |
| E3 Ubiquitin Ligase Traf3Ip2 | POSITIVELY REGULATES | Interleukin-17 Signaling |
| Iguratimod | NEGATIVELY REGULATES | Inhibitor Of Nuclear Factor Kappa-B Kinase Subunit Epsilon |
| Inhibitor Of Nuclear Factor Kappa-B Kinase Subunit Epsilon | POSITIVELY REGULATES | Interleukin-17 Signaling |
| Interleukin-17 Signaling | POSITIVELY REGULATES | Inflammatory Response |
| Iguratimod | POSITIVELY REGULATES | Cytoplasmic Sequestering Of Nf-Kappab |
| Cytoplasmic Sequestering Of Nf-Kappab | NEGATIVELY REGULATES | Tnfrsf Mediated Non-Canonical Nf-Kb Pathway |
| Tnfrsf Mediated Non-Canonical Nf-Kb Pathway | POSITIVELY REGULATES | Inflammatory Response |
| Prostaglandin G/H Synthase 2 | POSITIVELY REGULATES | Inflammatory Response |
| Inflammatory Response | POSITIVELY CORRELATED WITH | Rheumatoid Arthritis |
|---------|-----------|---------|

Comment: Iguratimod (IGU) is a novel synthetic small molecule disease modified anti-rheumatic drug approved only in Japan and China. The mechanism of action is broadly reported as anti-inflammatory, immunomodulatory and osteoprotective mechanism.

Reference: 
  - [https://go.drugbank.com/drugs/DB12233](https://go.drugbank.com/drugs/DB12233)
  - [https://pubmed.ncbi.nlm.nih.gov/31918275/](https://pubmed.ncbi.nlm.nih.gov/31918275/)
  - [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054862/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054862/)
